0
Abstract: Poster Presentations |

CYSTEINYL LEUKOTRIENE LEVELS IN BRONCHOALVEOLAR LAVAGE FLUID OF PEDIATRIC LUNG TRANSPLANT RECIPIENTS FREE TO VIEW

Binal S. Kancherla, MD*; Marc Schecter, MD; Haibin Zhang, MD; John Robertson, MD; Minh Doan, MD; Jeffrey S. Heinle, MD; Emmett D. McKenzie, MD; George Mallory, MD; Okan Elidemir, MD
Author and Funding Information

Baylor College of Medicine, Houston, TX


Chest


Chest. 2007;132(4_MeetingAbstracts):606b. doi:10.1378/chest.132.4_MeetingAbstracts.606b
Text Size: A A A
Published online

Abstract

PURPOSE: Cysteinyl leukotrienes (Cys-LT) are known to cause local and systemic inflammatory responses. Elevated levels of Cys-LT have been investigated in graft dysfunction and rejection after solid organ transplantation. These effects in lung transplant recipients are not well defined. We hypothesized that Cys-LT levels in bronchoalveolar lavage (BAL) fluid would be elevated in lung transplant recipients with bronchiolitis obliterans syndrome (BOS), a clinical correlate of chronic airway rejection.

METHODS: Patients with and without BOS were identified by retrospective chart review using spirometry data. Cys-LT levels were measured in previously collected and stored BAL samples by ELISA. Paired student t-test was used to investigate the differences between the two groups.

RESULTS: Nine specimens were collected from patients with a diagnosis of BOS (Stage 1 or higher) and 23 specimens were collected from patients without any evidence of rejection, infection or BOS. Mean (±SEM) Cys-LT level in the BOS group was 8128 (±4922) pg/ml compared to 2708 (±978) pg/ml in the non-BOS group (p=0.14).

CONCLUSION: Patients with BOS had a higher mean Cys-LT level in the BAL fluid compared to patients without BOS. There was no statistically significant difference between the levels of Cys-LT in patients with and without BOS.

CLINICAL IMPLICATIONS: Further studies are needed to investigate the role of arachidonic acid metabolites in the development of graft dysfunction after lung transplantation.

DISCLOSURE: Binal Kancherla, No Financial Disclosure Information; No Product/Research Disclosure Information

Wednesday, October 24, 2007

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543